STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET,
TICKER: STENO
The Board of Directors and the Chief Executive Officer of
"2023 WAS ABOUT SECURING PRODUCT APPROVALS, SALES GROWTH AND STRENTHENING OF OUR BALANCE SHEET WE MADE STRONG PROGRESS IN ALL AREAS
Uniquely, we have built and secured individual national licenses to sell a portfolio of 10 approved oil products in our 5 markets and plan to launch more the year(s) to come. This is an unmatched platform for our ambitions to reach a) gross sales of 15 mDKK in 2024 and b) break-even by the end of the year.
In 2023, our execution on the four strategic assets paid off:
- Regulatory: We continued to be the only company in
Denmark to a) have medical cannabis oil products under the Danish Pilot program and b) make them available for patients. We also had new products approved for sales inGermany andAustralia . - Supply chain: As mentioned above, We have a strong product portfolio for patients in five markets. We continued to strengthen our supply relation with our key suppliers and optimize logistics. Also, our own factory is coming closer to commercial launch of own products.
- Commercial: We are actively selling prescription based oil products in 5 markets, and
Germany is the latest new market. We ended the year with a record total gross sale of 6,9 mDKK. - Partnerships: With our development partners, we entered a new phase for our innovative new patented oil technology. We contracted an experienced manufacturer to assist us in producing the next generation medical cannabis oil product, that will be branded as "Astrum oil" when it reaches the market during 2024.
For additional information regarding
About
www.stenocare.dk www.stenocare.se www.stenocare.com
https://news.cision.com/stenocare/r/stenocare-a-s-publishes-annual-report-2023,c3945642
https://mb.cision.com/Main/17551/3945642/2667959.pdf
https://mb.cision.com/Public/17551/3945642/96c5be5290a39a3d.pdf
(c) 2024 Cision. All rights reserved., source
